Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkae260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Samantha L Sarli und 12 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA. Hauptthemen laut MEDLINE: Glioblastoma, RNA, Small Interfering, Xenograft Model Antitumor Assays, Brain Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Glioblastoma multiforme is a universally lethal brain tumor that largely resists current surgical and drug interventions. Despite important advancements in understanding GBM biology, the invasiveness and heterogeneity of these tumors has made it challenging to develop effective therapies. Therapeutic oligonucleotides—antisense oligonucleotides and small-interfering RNAs—are chemically modified nucleic acids that can silence gene expression in the brain. However, activity of these oligonucleotides in brain tumors remains inadequately characterized. In this study, we developed a quantitative method to differentiate oligonucleotide-induced gene silencing in orthotopic GBM xenografts from gene silencing in normal brain tissue, and used this method to test the differential silencing activity of a chemically diverse panel of oligonucleotides. We show that oligonucleotides chemically optimized for pharmacological activity in normal brain tissue do not show consistent activity in GBM xenografts. We then survey multiple advanced oligonucleotide chemistries for their activity in GBM xenografts. Attaching lipid conjugates to oligonucleotides improves silencing in GBM cells across several different lipid classes. Highly hydrophobic lipid conjugates cholesterol and docosanoic acid enhance silencing but at the cost of higher neurotoxicity. Moderately hydrophobic, unsaturated fatty acid and amphiphilic lipid conjugates still improve activity without compromising safety. These oligonucleotide conjugates show promise for treating glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
- Department of Chemistry, McGill University, Montréal, Québec, Canada.
- Program in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA.
- Department of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
ORCID-Profile: Chantal M Ferguson, Dimas Echeverria, Jonathan K Watts
Förderung
- NCI NIH HHS
- NINDS NIH HHS
- NIH HHS
- NIGMS NIH HHS
- American Cancer Society
- NIH
Zitieren
APA
Sarli, S. L., Fakih, H. H., Kelly, K., Devi, G., Rembetsy-Brown, J. M., McEachern, H. R., Ferguson, C. M., Echeverria, D., Lee, J., Sousa, J., Sleiman, H. F., Khvorova, A., & Watts, J. K. (2024). Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae260
Vancouver
Sarli SL, Fakih HH, Kelly K, Devi G, Rembetsy-Brown JM, McEachern HR, et al. Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae260
BibTeX
@article{Sarli2024,
author = {Sarli, Samantha L and Fakih, Hassan H and Kelly, Karen and Devi, Gitali and Rembetsy-Brown, Julia M and McEachern, Holly R and Ferguson, Chantal M and Echeverria, Dimas and Lee, Jonathan and Sousa, Jacquelyn and Sleiman, Hanadi F and Khvorova, Anastasia and Watts, Jonathan K},
title = {Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkae260}
}
EUVIMED